24 May 2021 | 08:43am
StockMarketWire.com - Pharmaceutical company 4D Pharma provided additional positive data from its completed phase 2 trial of LBP Blautix to treat irritable bowel syndrome with constipation or with diarrhea. Further analysis of the data has revealed strong and statistically significant activity on the key symptom of bowel habit, a potential approvable primary endpoint per regulatory guidelines, the company said.
4D pharma previously announced topline efficacy and safety results from the trial, conducted in the US, UK and Ireland, in October 2020.
In the post-hoc sub-group analysis, statistically significant improvements in bowel habit in IBS-D, and a strong effect nearing significance in IBS-C were seen in patients across all geographic regions.
1 March 2021 | 08:31am
StockMarketWire.com - Pharmaceutical company 4D pharma said it had appointed John Beck as chief financial Officer.
Most recently Beck was the senior vice president, finance and CFO of Ritter Pharmaceuticals from May 2018 to May 2020, where he oversaw its successful merger with Qualigen Therapeutics, Inc.
At 8:31am: [LON:DDDD] 4d Pharma Plc Ord 0.25p share price was 0p at 95.6p
Story provided by StockMarketWire.com
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.
Latest share price and company details:
8 February 2021 | 08:36am
StockMarketWire.com - Pharmaceutical company 4D pharma said it had signed a clinical trial collaboration and supply agreement with Merck in Germany and Pfizer for an immunotherapy approved as a first-line maintenance treatment for patients with urothelial cancer.
Bavencio was co-developed and co-commercialized by Merck KGaA, Darmstadt, Germany and Pfizer.
Under the collaboration, 4D pharma intended to commence a clinical trial in 2021 to evaluate Bavencio in combination with MRx0518 as a first-line maintenance therapy for patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy, the company said.
At 8:36am: [LON:DDDD] 4d Pharma Plc Ord 0.25p share price was 0p at 95.6p
Share price
4D pharma to complete enrolment of combination trials in Q4; expects results from pancreatic cancer in 2021
3 February 2021 | 09:48am
StockMarketWire.com - Pharmaceutical company 4D pharma said it expected to complete enrolment for Part B of the clinical trial assessing its lead cancer drug MRx0518 combined with Keytruda in the fourth quarter and receive initial results from its pancreatic cancer trial later this year.
Part A of the study included an initial safety phase assessing dose, while the part B cohort expansion phase assessed clinical benefit in addition to safety.
The company said 24 additional patients across five active US sites had now been treated in part B of this ongoing study, with target tumor reductions having been observed at the nine weeks.
18 December 2020 | 14:04pm
StockMarketWire.com - 4D pharma said it has joined the Parkinson s Progression Markers Initiative (PPMI), a study sponsored by The Michael J Fox Foundation (MJFF) to better understand Parkinson s disease and accelerate the development of new treatments.
The study was launched by MJFF in 2010 to help identify, develop, and validate biomarkers of Parkinson s disease progression to further the development of disease-modifying therapies.
PPMI is funded by MJFF and a consortium of key industry players, non-profit organizations and private individuals, and involves active participation of stakeholders from government, the biopharmaceutical industry and academia.
Alex Stevenson, chief scientific officer at 4D pharma said: The Michael J Fox Foundation has made considerable contributions to the development of therapeutic solutions for the millions of people with Parkinson s disease.